[Tremor and motility following oxotremorine and harmine in rats with lesions of the nigro-striatal system].
D000470:Alkaloids / Q000037:antagonists & inhibitors*; D000818:Animals; D002421:Caudate Nucleus / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D004298:Dopamine / Q000032:analysis / Q000378:metabolism; D005260:Female; D005917:Globus Pallidus / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000494:pharmacology; D006892:Hydroxydopamines / Q000008:administration & dosage / Q000627:therapeutic use; D007211:Indoles / Q000037:antagonists & inhibitors*; D009043:Motor Activity / Q000187:drug effects*; D009434:Neural Pathways / Q000502:physiology; D018377:Neurotransmitter Agents / Q000378:metabolism; D009638:Norepinephrine / Q000032:analysis / Q000378:metabolism; D010095:Oxotremorine / Q000037:antagonists & inhibitors*; D051381:Rats; D012688:Septum Pellucidum / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects*; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced
D000470:Alkaloids; D006571:Heterocyclic Compounds; D006892:Hydroxydopamines; D007211:Indoles; D018377:Neurotransmitter Agents; D010095:Oxotremorine; D004298:Dopamine; D009638:Norepinephrine
Tremor und Motorik nach Oxotremorin- und Harmin-Applikation bei Ratten mit Läsionen des nigro-striatalen Systems